Pharmafile Logo
Pharmafocus logo
Advanced Search

NMOSD

Showing 3 posts of 3 posts found.

robina-weermeijer-ihfopazzjhm-unsplash_5

AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

May 30, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …

News

AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD

May 11, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology

AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …

News
images

Roche’s satralizumab succeeds in second positive study in rare CNS disease

September 12, 2019
Research and Development NMOSD, Roche, satralizumab

In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024